David’s initial research was the investigation of the role of cytokines in bone metabolism, and through his PhD (The University of Sheffield, 1988) he developed an interest in understanding the mechanism of action of bisphosphonates.
He developed this interest during his sabbatical as a Visiting Assistant Professor at the University of Texas Health Science Center, San Antonio, establishing the pro-apoptotic effect of bisphosphonates on osteoclasts. During his Clinical Lectureship at the University of Sheffield he contributed to the work of the team of Professor Mike Rogers in demonstrating the role of the mevalonate pathway in bisphosphonate action.
Recently, David has worked collaboratively using his skills in tissue interpretation to contribute to a variety of projects such as describing the phenotype of IL-1 receptor antagonist knockout mice and tissue engineering using conditionally-immortalised chondrocyte progenitors. David currently collaborates with Professor Peter Croucher’s group and contributes histology support to the Sheffield Bone Biomedical Research Unit. He is also the reference pathologist for the national VORTEX and Axitinib-STS sarcoma clinical trials.